{"id":"NCT03864614","sponsor":"Biogen","briefTitle":"A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)","officialTitle":"A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With SAGE-217 in Adult Subjects With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-27","primaryCompletion":"2023-06-22","completion":"2023-06-22","firstPosted":"2019-03-06","resultsPosted":"2024-07-18","lastUpdate":"2024-08-27"},"enrollment":1515,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"SAGE-217","otherNames":[]}],"arms":[{"label":"SAGE-217","type":"EXPERIMENTAL"}],"summary":"This is a Phase 3, open-label, 1-year study of the safety, tolerability, and need for re-treatment with SAGE-217 in adult participants with MDD.","primaryOutcome":{"measure":"Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 52 Weeks","effectByArm":[{"arm":"Part A: Sage-217 High-dose Cohort","deltaMin":374,"sd":null},{"arm":"Part A: Sage-217 Low-dose Cohort","deltaMin":437,"sd":null},{"arm":"Part A: Sage-217 Dose-switch Cohort","deltaMin":57,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States"]},"refs":{"pmids":["38153320"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":513},"commonTop":["Somnolence","Headache","Dizziness","Sedation","Upper respiratory tract infection"]}}